Payment overview · 2025
General Payments
$63.88
3 reported records · 3 companies
Healthcare provider profile · identity verified
Keith M Lipsmeyer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MORRILTON, AR · NPI 1528055738
Verified facts
What the public records show
CMS Open Payments records show Keith M Lipsmeyer, M.D. received $63.88 in general payments during 2025 across 3 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $26.18 | 41.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.03 | 29.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.67 | 29.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $63.88 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $26.18 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.03 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $18.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 178 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
178 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 675 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 630 | 140 |
| Pravastatin Sodium | Pravastatin Sodium | 492 | 117 |
| Lisinopril | Lisinopril | 396 | 96 |
| Losartan Potassium | Losartan Potassium | 385 | 95 |
| Omeprazole | Omeprazole | 356 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 89 |
| Hydrochlorothiazide | Hydrochlorothiazide | 327 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 274 | 77 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 248 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 59 |
| Carvedilol | Carvedilol | 243 | 54 |
| Alprazolam | Alprazolam | 231 | 30 |
| Metformin Hcl | Metformin Hcl | 231 | 51 |
| Furosemide | Furosemide | 228 | 60 |
| Oxycodone Hcl | Oxycodone Hcl | 211 | 22 |
| Glipizide Er | Glipizide | 209 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 178 | 28 |
| Trazodone Hcl | Trazodone Hcl | 174 | 47 |
| Atenolol | Atenolol | 170 | 40 |
| Diazepam | Diazepam | 170 | 38 |
| Potassium Chloride | Potassium Chloride | 168 | 33 |
| Famotidine | Famotidine | 165 | 39 |
| Eliquis | Apixaban | 161 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 49 |
| Gabapentin | Gabapentin | 153 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 37 |
| Amitriptyline Hcl | Amitriptyline Hcl | 139 | 33 |
| Simvastatin | Simvastatin | 131 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 40 |
| Allopurinol | Allopurinol | 123 | 26 |
| Montelukast Sodium | Montelukast Sodium | 123 | 23 |
| Lovastatin | Lovastatin | 121 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 118 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 112 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 106 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 103 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 26 |
| Pregabalin | Pregabalin | 98 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 20 |
| Tramadol Hcl | Tramadol Hcl | 93 | 25 |
| Jardiance | Empagliflozin | 91 | 20 |
| Propranolol Hcl | Propranolol Hcl | 89 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 24 |
| Estradiol | Estradiol | 85 | 20 |
| Meloxicam | Meloxicam | 83 | 28 |
| Lorazepam | Lorazepam | 82 | 18 |
| Buspirone Hcl | Buspirone Hcl | 78 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 18 |
| Metformin Hcl Er | Metformin Hcl | 77 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 14 |
| Spironolactone | Spironolactone | 66 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 18 |
| Mirtazapine | Mirtazapine | 61 | 16 |
| Sertraline Hcl | Sertraline Hcl | 61 | 11 |
| Warfarin Sodium | Warfarin Sodium | 60 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 59 | 16 |
| Amoxicillin | Amoxicillin | 58 | 46 |
| Finasteride | Finasteride | 55 | 15 |
| Azithromycin | Azithromycin | 54 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 11 |
| Fluconazole | Fluconazole | 50 | 24 |
| Prednisone | Prednisone | 50 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 13 |
| Fentanyl | Fentanyl | 49 | suppressed |
| Clonazepam | Clonazepam | 46 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 45 | 12 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 11 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Cephalexin | Cephalexin | 40 | 33 |
| Ozempic | Semaglutide | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 15 |
| Carisoprodol | Carisoprodol | 38 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 36 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 34 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 28 |
| Morphine Sulfate Er | Morphine Sulfate | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Methadone Hcl | Methadone Hcl | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 17 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $63.88 · 3 records | Otsuka America Pharmaceutical, Inc. | AIRSUPRA, REXULTI, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error